Stocktoria
GRI Bio, Inc. GRI
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-02-10
GRI Bio, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | $100,000 |
| R&D expense | $6.8M | $3.8M | $3.2M | $242,000 | $5.2M | $3.7M |
| Operating income | -$12.0M | -$8.2M | -$11.4M | -$2.2M | -$9.3M | -$4.8M |
| Income tax | $3,000 | $2,000 | — | — | — | — |
| Net income | -$12.0M | -$8.2M | -$13.0M | -$3.2M | -$9.3M | -$4.8M |
| EPS (diluted) | $-121.80 | $-1545.55 | $-5018.09 | $-24.95 | $-1.42 | $-1.07 |
| Operating cash flow | -$10.2M | -$8.6M | -$9.0M | -$1.1M | -$8.3M | -$3.7M |
| Free cash flow | -$10.2M | -$8.6M | -$9.0M | -$1.1M | -$8.3M | -$3.7M |
| Cash & equivalents | $8.2M | $5.0M | $1.8M | $9,000 | $3.7M | $109,000 |
| Total assets | $8.7M | $5.7M | $3.0M | $383,000 | $8.3M | $955,000 |
| Total liabilities | $2.7M | $1.7M | $2.7M | $2.0M | $2.5M | $2.4M |
| Shareholders' equity | $6.0M | $4.0M | $259,000 | -$1.6M | -$4.8M | -$1.5M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | -100.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.